Business Context and Reporting Period
This Form 8-K Current Report was filed by Zimmer Biomet Holdings, Inc. on November 15, 2021. The filing discloses the entry into a material definitive agreement regarding a public debt offering.
Key Financial Metrics and Transaction Details
The Company entered into an underwriting agreement to issue two tranches of senior notes with a total aggregate principal amount of $1.6 billion:
- 2024 Notes: $850.0 million aggregate principal amount, bearing interest at 1.450% per annum, maturing November 22, 2024.
- 2031 Notes: $750.0 million aggregate principal amount, bearing interest at 2.600% per annum, maturing November 24, 2031.
Interest on both tranches is payable semi-annually in arrears. The sale of the Notes is scheduled to close on November 24, 2021, subject to customary closing conditions.
Material Changes and Use of Proceeds
The filing does not report changes to historical revenue, profit, or operating margins. The material change is the expansion of the Company's debt capital structure. The net proceeds from the offering are intended to be used for:
- Repayment of other indebtedness.
- Funding cash tender offers for certain outstanding debt securities commenced on November 15, 2021.
- General corporate purposes.
Guidance, Risks, and Contingencies
The filing contains forward-looking statements regarding the closing of the offering and the intended use of proceeds. Management notes that actual outcomes may differ materially due to risks, including the possibility that the offering is not consummated on anticipated terms. The Company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Confirm the closing of the $1.6 billion note offering on or before November 24, 2021.
- Verify the specific allocation of net proceeds between debt repayment, tender offers, and general corporate purposes.
- Review the impact of the new debt issuance on the Company's overall leverage ratios and liquidity position.
- Monitor the status of the concurrent cash tender offers for outstanding debt securities.